Company: PSTV
Filing Date: 2025-03-31
Form Type: 10-K
Source: 0000950170-25-047698
Chunk: 183

Company: PLUS THERAPEUTICS, INC.
Filing Date: 2025-03-31
Form: 10-K
Item: Item 8
Chunk 183
---
.60

        $
        -

97

 The Company settles exercises of stock options with newly issued shares of its common stock. There were no stock options exercised in 2024 or 2023. The estimated fair value of options, including the effect of estimated forfeitures, is recognized over the requisite service period, which is typically the vesting period of each option. The fair value of each option awarded during the years ended December 31, 2024 and 2023 was estimated on the date of grant using the Black-Scholes-Merton option valuation model based on the following weighted-average assumptions: 

        December 31,2024
         
        December 31,2023

        Expected term
        6.0 years
         
        6.0 years

        Risk-free interest rate
         
        3.79
        %
         
        4.06
        %

        Expected volatility
         
        120.6
        %
         
        127.0
        %

        Dividends
         
        0
        %
         
        0
        %

        Resulting fair value
        $
        1.39
         
        $
        4.47

       The weighted average risk-free interest rate represents the interest rate for treasury constant maturity instruments published by the Federal Reserve Board. If the term of available treasury constant maturity instruments is not equal to the expected term of an employee option, the Company uses the weighted average of the two Federal Reserve securities closest to the expected term of the employee option.The dividend yield has been assumed to be zero as the Company (a) has never declared or paid any dividends and (b) does not currently anticipate paying any cash dividends on its outstanding shares of common stock in the foreseeable future.The following table summarizes share-based compensation recognized during the years ended December 31, 2024 and 2023 in the statement of operations (in thousands):  

        Years ended December 31,

        2024

        2023

        Research and development
         
        $
        51

        $
        66

        General and administrative

        499

        503

        Total share-based compensation
         
        $
        550

        $
        569

       As of December 31, 2024, the total compensation cost related to non-vested stock options and stock awards not yet recognized for all our plans is approximately $